Active immunotherapy in HER2 overexpressing breast cancer: Current status and future perspectives

Annals of Oncology

Volumn 24, Issue 7, 2013, Pages 1740-1748

  Milani, A ^a,b   Sangiolo, D ^a,b   Montemurro, F ^a,c   Aglietta, M ^a,b   Valabrega, G ^a,b  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Fondazione del Piemonte per l'Oncologia   (Italy)

Author keywords

Active immunotherapy; Breast cancer; HER2; Vaccine

Indexed keywords

AE37 PEPTIDE; CANCER VACCINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FREUND ADJUVANT; GP2 PEPTIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LAPATINIB; LAPULEUCEL T; NAVELBINE; NELIPEPIMUT S; PEPTIDE VACCINE; POLYGLACTIN; TRASTUZUMAB; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACTIVE IMMUNIZATION; BREAST CANCER; BREAST CARCINOMA; CANCER SURVIVAL; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LUNG CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; OVARY CARCINOMA; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACTIVE IMMUNOTHERAPY; BREAST CANCER; HER2; VACCINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGEN-PRESENTING CELLS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84883759491     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt133     Document Type: Review

References (67)

1. Ladjemi MZ, Jacot W, Chardes T et al. Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 2010; 59: 1295-312.
2. Disis ML, Calenoff E, McLaughlin G et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54: 16-20.
3. Peoples GE, Goedegebuure PS, Smith R et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A 1995; 92: 432-436.
4. Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119.
5. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-4274.
6. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
7. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791.
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
9. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
10. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-1283.
11. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.
12. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
13. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
14. van EA, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190: 355-366.
15. Li B, VanRoey M, Wang C et al. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res 2009; 15: 1623-1634.
16. Fisk B, Blevins TL, Wharton JT et al. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181: 2109-2117.
17. Schendel DJ, Gansbacher B, Oberneder R et al. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993; 151: 4209-4220.
18. Knutson KL, Disis ML. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine. Clin Breast Cancer 2001; 2: 73-79.
19. Disis ML, Gooley TA, Rinn K et al. Generation of T-cell immunity to the HER-2/ neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002; 20: 2624-2632.
20. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 1998; 58: 4902-4908.
21. Disis ML, Grabstein KH, Sleath PR et al. Generation of immunity to the HER-2/ neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999; 5: 1289-1297.
22. Knutson KL, Schiffman K, Cheever MA et al. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptidespecific immunity. Clin Cancer Res 2002; 8: 1014-1018.
23. Murray JL, Gillogly ME, Przepiorka D et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 2002; 8: 3407-3418.
24. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001; 107: 477-484.
25. Salazar LG, Goodell V, O'Meara M et al. Persistent immunity and survival after immunization with a HER2/neu (HER2) vaccine. ASCO Meeting Abstracts 2009; 27(15S): 3010.
26. Peoples GE, Gurney JM, Hueman MT et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005; 23: 7536-7345.
27. Peoples GE, Holmes JP, Hueman MT et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008; 14: 797-803.
28. Amin A, Benavides LC, Holmes JP et al. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol Immunother 2008; 57: 1817-1825.
29. Holmes JP, Gates JD, Benavides LC et al. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2008; 113: 1666-1675.
30. Benavides LC, Gates JD, Carmichael MG et al. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2009; 15: 2895-2904.
31. Mittendorf EA, Clifton GT, Holmes JP et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2012; 118: 2594-2602.
32. Mittendorf EA, Storrer CE, Foley RJ et al. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 2006; 106: 2309-2317.
33. Carmichael MG, Benavides LC, Holmes JP et al. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer 2010; 116: 292-301.
34. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54: 721-728.
35. Mittendorf EA, Holmes JP, Murray JL et al. CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37). Expert Opin Biol Ther 2009; 9: 71-78.
36. Holmes JP, Benavides LC, Gates JD et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008; 26: 3426-3433.
37. Hale DF, Perez SA, Vreeland TJ et al. An assessment of disease features and immune response in breast cancer patients that did not recur after receiving HER2 peptide, AE37 vaccine in a randomized phase II trial. ASCO Meeting Abstracts 2012; 30(15_suppl): 625.
38. Vreeland TJ, Hale DF, Sears AK et al. From bench to bedside: the use of the li-Key technology to improve helper peptides for clinical use in cancer vaccines. ASCO Meeting Abstracts 2012; 30(15_suppl): 2508.
39. Patil R, Clifton GT, Holmes JP et al. Clinical and immunologic responses of HLAA3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial. J Am Coll Surg 2010; 210: 140-147.
40. Mittendorf EA, Holmes JP, Ponniah S et al. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother 2008; 57: 1511-1521.
41. Berinstein NL, Karkada M, Nigam R et al. Effect of the novel therapeutic cancer vaccine formulation DPX-0907 on multifunctional T-cell responses in ovarian, breast, and prostate cancer patients. ASCO Meeting Abstracts 2012; 30 (15_suppl): 2588.
42. Dela Cruz JS, Lau SY, Ramirez EM et al. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine 2003; 21: 1317-1326.
43. Disis ML, Schiffman K, Guthrie K et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine. J Clin Oncol 2004; 22: 1916-1925.
44. Limentani S, Dorval T, White S et al. Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/III HER2+ breast cancer. ASCO Meeting Abstracts 2005; 23(16_suppl): 2520.
45. Prud'homme GJ. DNA vaccination against tumors. J Gene Med 2005; 7: 3-17.
46. Gallo P, Dharmapuri S, Nuzzo M et al. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 2005; 113: 67-77.
47. Orlandi F, Venanzi FM, Concetti A et al. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. Clin Cancer Res 2007; 13: 6195-6203.
48. Yo YT, Hsu KF, Shieh GS et al. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine. Cancer Gene Ther 2007; 14: 904-917.
49. Guardino A, Cassidy M, Pienkowski T et al. Results of two phase I clinical trials of MVA-BN(R)-HER2 in HER-2 overexpressing metastatic breast cancer patients. Cancer Res 2010; 69(24_suppl): 5089.
50. Curigliano G, Spitaleri G, Pietri E et al. Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol 2006; 17: 750-62.
51. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004; 363: 594-599.
52. Emens LA, Asquith JM, Leatherman JM et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy doseranging factorial study of safety and immune activation. J Clin Oncol 2009; 27: 5911-5918.
53. Rohrbach F, Weth R, Kursar M et al. Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity. J Immunol 2005; 174: 5481-5489.
54. Nabekura T, Nagasawa T, Nakauchi H et al. An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2. Cancer Immunol Immunother 2008; 57: 611-622.
55. Brossart P, Wirths S, Stuhler G et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96: 3102-3108.
56. Czerniecki BJ, Koski GK, Koldovsky U et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007; 67: 1842-1852.
57. Bahl S, Roses RE, Sharma A et al. Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/ neu-pulsed dendritic cell vaccines. Am J Surg 2009; 198: 488-494.
58. Morse MA, Hobeika A, Osada T et al. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J Transl Med 2007; 5: 42.
59. Peethambaram PP, Melisko ME, Rinn KJ et al. A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res 2009; 15: 5937-5944.
60. Disis ML, Wallace DR, Gooley TA et al. Concurrent trastuzumab and HER2/neuspecific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009; 27: 4685-4692.
61. Emens LA, Gupta R, Petrik S et al. A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ metastatic breast cancer. ASCO Meeting Abstracts 2011; 29(15_suppl): 2535.
62. Norell H, Poschke I, Charo J et al. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med 2010; 8: 53.
63. Disis M, Dang Y, Bates N et al. Phase II study of a HER-2/Neu (HER2) intracellular domain (ICD) vaccine given concurrently with trastuzumab in patients with newly diagnosed advanced stage breast cancer. Cancer Res 2010; 69 (24_suppl): 5102.
64. Hamilton E, Blackwell K, Hobeika AC et al. Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion. J Transl Med 2012; 10: 28.
65. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, openlabel, phase 2 trial. Lancet Oncol 2012; 13: 25-32.
66. Untch M, Loibl S, Bischoff J et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012; 13: 135-144.
67. Morgan RA, Yang JC, Kitano M et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18: 843-851.